Milestone Pharmaceuticals Inc
MIST
Company Profile
Business description
Milestone Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of cardiovascular medicines. Its approved product CARDAMYST (etripamil) nasal spray is available in the United States and is the self-administered treatment for use by patients anywhere, anytime an attack of PSVT occurs. It operates in single segment.
Contact
1111 Dr. Frederik-Phillips Boulevard
Suite 420
MontrealQCH4M 2X6
CANT: +1 514 336-0444
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
38
Stocks News & Analysis
stocks
The SpaceX IPO and the Elon Musk factor
Potential investors should remember that the company’s controlling shareholder can move markets with a few words.
stocks
The ASX’s most shorted stocks in 2026
What we can and can’t learn from the top 20 most shorted ASX shares.
stocks
ASX energy producers: Energy prices rise sharply as global tensions flare, but long-term view unchanged
Our view on the chaotic energy markets.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,657.50 | 2.20 | 0.03% |
| CAC 40 | 7,724.25 | 22.30 | 0.29% |
| DAX 40 | 22,351.12 | 50.37 | 0.23% |
| Dow JONES (US) | 45,166.64 | 793.47 | -1.73% |
| FTSE 100 | 10,045.13 | 77.78 | 0.78% |
| HKSE | 24,750.79 | 201.09 | -0.81% |
| NASDAQ | 20,948.36 | 459.72 | -2.15% |
| Nikkei 225 | 51,885.85 | 1,487.22 | -2.79% |
| NZX 50 Index | 12,748.92 | 186.47 | -1.44% |
| S&P 500 | 6,368.85 | 108.31 | -1.67% |
| S&P/ASX 200 | 8,461.00 | 0.10 | 0.00% |
| SSE Composite Index | 3,923.29 | 9.56 | 0.24% |